Isolation of a tumor factor responsible for angiogenesis
Open accessAbstract
Human and animal solid tumors elaborate a factor which is mitogenic to capillary endothelial cells. This factor has been called tumor-angiogenesis factor. The important components of TAF are RNA and protein. It is suggested that blockade of this factor (inhibition of angiogenesis) might arrest solid tumors at a tiny diameter of a few millimeters.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
As a tumor expands beyond ~1-2 mm3, limited diffusion results in hypoxic regions that drive tumor dormancy.
“As the tumor expands beyond this size, the limited diffusion capacity results in the formation of hypoxic regions, which drive tumor dormancy [50,51].”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [50]
The Discussion (immediately before p. 288) says a small tumor colony can reach a size at which diffusion of nutrients and wastes is insufficient, and suggests that blocking angiogenesis might arrest growth. It does not identify hypoxic regions as the cause of dormancy or give a 1–2 mm³ threshold; the opening passage instead reports a 3–4 mm diameter growth limit in isolated perfused organs. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · see citing works
Self-citationDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · see citing works
Regulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520 · see citing works
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262 · see citing works
Benavente-García, O., & Castillo, J. (2008) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf8006568 · Cited by 1,158 · see citing works
Weidemann, A., & Johnson, R. S. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.12 · Cited by 941 · see citing works
Mechanisms of normal and tumor-derived angiogenesis
Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809 · see citing works
A history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502 · see citing works
Angiogenesis in the atherosclerotic plaque
Camaré, C., Pucelle, M., Nègre-Salvayre, A., & Salvayre, R. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.007 · Cited by 401 · see citing works
Milanini, J., Viñals, F., Pouysségur, J., & Pagès, G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18165 · Cited by 315 · see citing works
Endothelial-cell proliferation in experimental tumours
Denekamp, J., & Hobson, B. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.263 · Cited by 237 · see citing works
Angiogenesis in Chronic Inflammatory Skin Disorders
Lee, H. J., Hong, Y. J., & Kim, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112035 · Cited by 211 · see citing works
Martinez-Outschoorn, U. E., Pestell, R. G., Howell, A., Tykocinski, M. L., Nagajyothi, F., Machado, F. S., Tanowitz, H. B., Sotgia, F., & Lisanti, M. P. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18487 · Cited by 157 · see citing works
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119 · see citing works
Greenaway, J., Moorehead, R., Shaw, P., & Petrik, J. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.035 · Cited by 100 · see citing works
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87 · see citing works
Shah, S., & D’Souza, G. G. M. (2025) · Cells · doi:10.3390/cells14100732 · Cited by 66 · see citing works
“As the tumor expands beyond this size, the limited diffusion capacity results in the formation of hypoxic regions, which drive tumor dormancy [50,51].”
- Authors
- Folkman, J., Merler, E., Abernathy, C., & Williams, G.
- Affiliations
- Boston Children's Hospital (US)
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1971-02-01
- Volume
- 133
- Issue
- 2
- Pages
- 275-288
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2138906
- OpenAlex
- W1975519085
- Cited by
- 1,663
- References
- 0
- Citations by year
- 2026: 5 · 2025: 35 · 2024: 21 · 2023: 32 · 2022: 35 · 2021: 46 · 2020: 36 · 2019: 33 · 2018: 53 · 2017: 44 · 2016: 60 · 2015: 52 · 2014: 51 · 2013: 65 · 2012: 51
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- angiogenesis, capillary endothelial cells, mitogenic factors, solid tumors, tumor growth inhibition, RNA, tumor proteins
- MeSH terms
- Animals, Blood Vessels, Capillaries, Carcinoma 256, Walker, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Melanoma, Mitosis, Neoplasm Transplantation, Neoplasms, Wilms Tumor, Neuroblastoma, Proteins, RNA, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
